BMS 986012

Drug Profile

BMS 986012

Alternative Names: Anti-fucosyl-GM1 - Bristol-Myers Squibb; BMS986012

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fucosyl GM1 ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Small cell lung cancer

Most Recent Events

  • 08 Sep 2017 Initial efficacy and adverse events data from a phase I/II trial in Small cell lung cancer (Combination therapy, Second line therapy) presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 29 Aug 2017 Bristol-Myers Squibb completes a phase I trial in Small cell lung cancer (Monotherapy) in Japan (IV) (NCT02949895)
  • 31 Oct 2016 Bristol-Myers Squibb plans a phase I trial for Small cell lung cancer in Japan (IV) (NCT02949895)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top